Grade A · clinically studied3 peptides · 46 studies
GLP-1 metabolic framework (Semaglutide / Tirzepatide)
GLP-1 / GIP-GLP-1 framework reflecting some of the densest human data in the library.
This is a description, not a protocol to follow
Everything below is a summary of what people report doing and what the literature contains. Nothing here is medical advice.
What the evidence actually supports
Supported in animals
Animal-model studies indexed · 2
Cell and in-vitro studies indexed · 2
Reviews and uncategorised studies · 12
Not established
Any effect in humans · 30 human studies indexed
Any benefit from combining them · no combination study in our index
Human dose, route or duration · no PK study indexed
Protocol details
The combination of Semaglutide and Tirzepatide has not been studied together in published research. Evidence exists for each compound individually, but no trials have specifically tested their effects in combination.
Semaglutide has been associated with significant weight reduction in a real-world setting, with a study reporting a 12.4% reduction from baseline over 24 months in a cohort of 500 participants [5]. Additionally, a strong correlation was found between weight loss at Week 8 and at six months, suggesting that early weight loss may predict longer-term outcomes [4]. However, it was noted that new-onset alopecia occurred in 4.5% of participants treated with Semaglutide, compared to 12.4% in those treated with Tirzepatide, indicating a difference in side effects between the two treatments [2].
Tirzepatide has been shown to improve glycemic control and promote weight loss in patients with type 2 diabetes, with a cost analysis indicating that its annual pharmacy cost was higher than that of Semaglutide [3]. However, no specific dosing regimens or detailed clinical outcomes were established for the combination of these two peptides.
Research on GLP-1 blends has indicated that certain dietary factors can influence GLP-1 secretion. For instance, a study found that meals containing animal-based saturated fats led to higher postprandial GLP-1 levels compared to unsaturated fats [6]. Another study demonstrated that a combination of Citrus aurantifolia and Theobroma cacao extracts significantly increased GLP-1 secretion in vitro, although the implications for human health remain unclear [14].
Sources
[2] New-Onset Alopecia Is Significantly Higher with Tirzepatide than with Semaglutide, Even After Weight-Loss Matching — 2020 https://doi.org/10.20944/preprints202607.1370.v1
[3] Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK. — 2026 https://doi.org/10.1080/13696998.2026.2631920
[4] What Week 8 Knows: Forecasting Six-Month GLP-1 Outcomes — 2023 https://doi.org/10.64898/2026.07.14.26357506
[5] Sustained weight reduction with once-weekly semaglutide: results from a real-world retrospective cohort study in the United States (SCOPE 24 months). — 2023 https://pubmed.ncbi.nlm.nih.gov/41351543/
[6] Sequential Meals Containing Animal and Plant-Based Saturated Fats Have Differential Effects on Postprandial Gut Hormones but No Impact on Satiety Compared with Unsaturated Fats in Generally Healthy Males: Findings from the Randomized Controlled Crossover CocoHeart Study. — 2023 https://pubmed.ncbi.nlm.nih.gov/40609691/
[14] Combination of Citrus aurantifolia Fruit Rind and Theobroma cacao Seed Extracts Stimulates Glucagon-Like Peptide-1 Secretion by Activating hTAS2Rs and the Phospholipase C-Mediated Signaling Pathway in NCI-H716 Cells. — 2025 https://pubmed.ncbi.nlm.nih.gov/41180086/
Research & studies for this protocol
46 rows · showing 24Newest first
| Study | Compound | Source | Year |
|---|---|---|---|
| This study compared sleeve gastrectomy, semaglutide therapy, and the DEAR weight management program in 53 patients with endometrial cancer. The primary outcome was weight loss and metabolic improvement over two years. Results indicated that sleeve gastrectomy led to the largest BMI reduction at one year, while the DEAR program showed better weight maintenance and metabolic stability at two years. | Semaglutide | europepmc | 2026 |
| This study compared the reporting of serious acute biliary events associated with glucagon-like peptide-1-based therapies, including tirzepatide, to sodium-glucose cotransporter-2 inhibitors in type 2 diabetes. The analysis included 114,102 eligible reports from 2013 Q2 to 2026 Q1. A primary reporting odds ratio of 1.36 was observed. | Tirzepatide | biorxiv-preprint | 2026 |
| This study investigated the effects of semaglutide and GIP peptide on skeletal muscle myotubes derived from older adults with obesity. The primary focus was on atrophy-related gene expression, secretome changes, and myotube morphology. No significant alterations were observed in these parameters following treatment. | Semaglutide | biorxiv-preprint | 2026 |
| This study evaluated longitudinal cardiac remodeling associated with semaglutide and tirzepatide in a cohort of 3,500 patients, stratified by weight loss. The findings indicated a decrease in left ventricular mass proportional to weight loss across different responder groups. No significant changes were observed in left atrial volume or left ventricular function. | Semaglutide | biorxiv-preprint | 2026 |
| This study evaluated the gastrointestinal (GI) motility effects of exenatide compared to semaglutide and tirzepatide using electronic health record data. The analysis included 387 patients on exenatide and found a significant increase in anti-constipation prescriptions over 12 months. No significant changes were observed in body weight or HbA1c for exenatide compared to the other GLP-1 receptor agonists. | Semaglutide | biorxiv-preprint | 2020 |
| This observational study compared the incidence of new-onset alopecia in users of tirzepatide versus semaglutide over a 12-month period. The study included 12,863 matched participants in each group, with findings indicating a higher incidence of alopecia with tirzepatide (4.20%) compared to semaglutide (2.88%). The results remained significant even after adjusting for weight loss. | Semaglutide | biorxiv-preprint | 2020 |
| This study assessed treatment satisfaction and experiences with tirzepatide among people with obesity or overweight (PwO) without type 2 diabetes, as reported by prescribing physicians. Data were collected from 199 PwO and 151 physicians between October 2023 and January 2025. High satisfaction rates were reported, with 84.4% of PwO having at least one obesity-related complication. | Tirzepatide | europepmc | 2026 |
| This study analyzed the characteristics of 11,215 patients who initiated the oral Wegovy (semaglutide) pill, distinguishing between 'GLP-starters' and 'GLP-switchers'. It found significant differences in pre-index cardiometabolic and neuropsychiatric burdens between the two groups. Notably, GLP-switchers had a higher prevalence of various health conditions compared to GLP-starters. | Semaglutide | biorxiv-preprint | 2026 |
| The SOUL trial evaluated the cardiovascular benefits of oral semaglutide in adults aged ≥50 years with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease. The study found a 14% reduction in the risk of major adverse cardiovascular events (MACE) associated with oral semaglutide. The analysis focused on the relationship between baseline or changes in HbA1c or BMI and these cardiovascular benefits. | Semaglutide | PubMed | 2026 |
| Not reported in abstract. | Semaglutide | PubMed | 2026 |
| This narrative review discusses the role of dietary fiber in pediatric gastrointestinal health, highlighting the inadequate intake levels among children. It emphasizes the association between low fiber consumption and gastrointestinal issues, particularly functional constipation, which affects a significant percentage of children globally. No specific treatment claims are made. | GLP-1 Blends | europepmc | 2026 |
| This study evaluated a sodium caprate (C10)-based tablet formulation with meglumine as a pH modifier for gastric peptide delivery. It was tested in dogs and humans, with a focus on bioavailability. The formulation showed a 57% increase in exposure in dogs compared to a sodium salcaprozate (SNAC)-based formulation. | GLP-1 Blends | europepmc | 2026 |
| This review evaluates the health effects and market applications of algal-derived peptides, focusing on their nutritional content and mechanistic actions. Limited human trials suggest modest improvements in various health metrics. The study highlights the need for standardized production and robust clinical evidence. | GLP-1 Blends | europepmc | 2026 |
| This study evaluated changes in diet quality, food cravings, dietary intake, and body composition during 24 weeks of GLP-1 receptor agonist therapy in adults with obesity. The analytic sample consisted of 28 participants initiating either semaglutide or tirzepatide, without structured nutrition intervention. Significant reductions in body weight and energy intake were observed, but diet quality and food cravings did not improve. | Tirzepatide | europepmc | 2026 |
| This study evaluated the annual pharmacy cost per patient achieving composite treatment endpoints with tirzepatide (5, 10, and 15 mg) versus subcutaneous semaglutide (1 mg) in patients with type 2 diabetes in the UK. The analysis found that tirzepatide was associated with lower costs for most treatment targets. No therapeutic claims are made. | Tirzepatide | europepmc | 2026 |
| This study presents an updated health economic model evaluating the long-term cost-effectiveness of tirzepatide (5, 10, 15.0 mg) versus diet and exercise in patients with obesity or overweight with complications. The model predicted incremental cost-effectiveness ratios (ICERs) ranging from £8,327 to £10,157 per QALY gained. No therapeutic claims are made. | Tirzepatide | europepmc | 2026 |
| This study measured the abundance of *Parasutterella excrementihominis* in 215 human subjects undergoing a non-surgical obesity therapy program. The study found that *P. excrementihominis* abundance decreased during the weight reduction phase and was positively correlated with improvements in insulin sensitivity. No treatment claims are made regarding the implications of these findings. | Semaglutide | europepmc | 2026 |
| This narrative review evaluates the cerebrovascular protective effects of GLP-1 receptor agonists (GLP-1RAs) in individuals with type 2 diabetes mellitus (T2DM). It synthesizes data from cardiovascular outcome trials, meta-analyses, and mechanistic studies, focusing on stroke prevention. The review highlights relative risk reductions for stroke ranging from 15% to 39%, depending on the agent and patient characteristics. | Semaglutide | europepmc | 2026 |
| This study evaluated the cost-effectiveness of tirzepatide versus semaglutide in individuals with obesity or overweight, using data from the SURMOUNT-5 trial. The analysis reported cost savings of $41,688 per patient and 0.506 QALYs gained with tirzepatide. No therapeutic claims are made. | Semaglutide | europepmc | 2026 |
| This study evaluated the association between GLP-1 receptor agonists (semaglutide and tirzepatide) and the risk of all-cause overdose in veterans with type 2 diabetes and opioid use disorder. The analysis included veterans who initiated these medications between January 1, 2020, and December 31, 2024. Results indicated a significantly lower risk of overdose when compared to insulin and SGLT2 inhibitors, but not to other diabetes medications. | Semaglutide | PubMed | 2026 |
| This study analyzed user-generated content on Reddit regarding perceptions of bariatric surgery and medication interventions for weight loss. A total of 1500 posts and 45,972 comments were examined, revealing various themes and sentiments. Notably, pre-intervention posts indicated higher levels of anxiety and depression compared to post-intervention posts. | Semaglutide | PubMed | 2026 |
| This study investigated the effects of tirzepatide on testicular inflammation and sperm DNA fragmentation in obese diabetic KK-Ay mice. Mice were treated with tirzepatide at doses of 1.00 nmol/kg/day or 0.16 nmol/kg/day for 8 weeks. The higher dose significantly reduced glycated hemoglobin A1c levels and improved sperm motility. | Tirzepatide | biorxiv-preprint | 2026 |
| This study evaluated the impact of tirzepatide-associated weight loss on incident frailty and mortality risk in adults aged 65 years or older. It measured various frailty-related phenotypes and their association with mortality, ICU admission, and hospitalization. Notably, increased weight loss correlated with higher rates of frailty-related conditions. | Tirzepatide | biorxiv-preprint | 2026 |
| This study compared the effectiveness and cost of compounded tirzepatide versus branded formulations in a cohort of patients. The primary outcome measured was six-month percent body weight loss among 7,271 patients, with results showing no significant difference between the two formulations. Cost savings varied depending on the branded price scenario faced by patients. | Tirzepatide | biorxiv-preprint | 2026 |